On August 17, 2013, Zhujiang Hotel, Guangzhou. The 6th "CSCO-South" Cancer Biotherapy and Molecular Targeted Therapy Forum was grandly opened under the auspices of Professor Luo Rongcheng, the chairman of the conference, the vice president of Nanfang Hospital, and the director of the tumor center.

        Participants in this conference are mainly domestic experts and scholars in tumor biotherapy, as well as authoritative experts from Stanford University and Hong Kong University of Science and Technology invited by the conference. At the conference, in-depth and extensive discussions on tumor biotherapy and molecular targeted therapy were conducted. Authoritative experts gave an academic report on the conference, expounding the current status, development prospects, development trends of international mainstream technology, and existing deficiencies in tumor biotherapy. Both have had a lively exchange, which has played a role in promoting the clinical and technological development of tumor biotherapy in my country.

        At the ACTL™ Targeted Anti-tumor Cellular Immune Technology Symposium jointly held by our company and Nanfang Hospital Cancer Center, we invited the patented technology inventors, Professor Liu Yong from Stanford University, and Professor Luo Rongcheng from Southern Hospital, Dr. Li Aimin, Hong Kong Science Professor Xie Yong from the university gave academic reports on tumor biotherapy and ACTL™ technology. The doctors at the meeting were very interested and raised their concerns about the clinical application of the only targeted anti-tumor cell immune technology in China. Professor Liu Yong One by one, they answered their questions patiently and in detail. Many clinical experts said that ACTL™ technology will be the trend of China's tumor biotherapy.

Professor Liu Yong's "CSCO-South" Conference Report

ACTL™ conference experts

Professor Liu Yong’s ACTL™ Symposium Report

Professor Liu Yong answers questions

Group photo of ACTL™ conference report experts